FDA
-
-
-
-
-
-
-
MacroGenics Appoints Eric Risser as President and Chief Executive Officer
-
-
-
-
-
-
-
Macrogenics (MGNX) Enters Into Agreement With TerSera Therapeutics for the Sale of MARGENZA
-
-
-
-
-
-
-
MacroGenics Earns $15 Million Milestone Following U.S. FDA Approval of ZYNYZ™ (retifanlimab-dlwr)
-
-
-
-
-
-
-
MacroGenics Provides Update on Corporate Progress and Second Quarter 2022 Financial Results
-
-
-
-
-
-
-
MacroGenics Provides Update on Corporate Progress and Third Quarter 2021 Financial Results
-
-
-
-
-
-
-
MacroGenics Provides Update on Corporate Progress and Second Quarter 2021 Financial Results
-
-
-
-
-
-
-
MacroGenics Announces Achievement of $10 Million Milestone Related to Retifanlimab Collaboration with Incyte
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

